TECH

Bio-Techne Corp.

72.69

USD

-0.02

-0.02%

Oct 30, 15:00 UTC -4

Open

Bio-Techne Corp. (TECH) Earnings

TECH Earnings Reports

Positive Surprise Ratio

TECH beat 25 of 42 last estimates.

60%

Next Report

Next Week

Date of Next Report

Nov 03, 2026

Estimate for Q1 27 (Revenue/ EPS)

$297.20M

$0.45

Implied change from Q2 26 (Revenue/ EPS)

-7.47%

-2.17%

Implied change from Q1 26 (Revenue/ EPS)

+3.71%

+7.14%

Bio-Techne Corp. earnings per share and revenue

On Aug 12, 2026, TECH reported earnings of 0.46 USD per share (EPS) for Q2 26, beating the estimate of 0.44 USD, resulting in a 3.95% surprise. Revenue reached 321.19 million, compared to an expected 320.97 million, with a 0.07% difference. The market reacted with a +0.11% price change (close before vs. close after earnings).

Looking ahead to Q1 27, -- analysts forecast an EPS of 0.45 USD, with revenue projected to reach 297.20 million USD, implying an decrease of -2.17% EPS, and decrease of -7.47% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Regeneron Pharmaceuticals Inc

Report Date

Oct 30, 2026 For Q3 26

Estimate

$16.47

Actual

$20.07

Surprise

+21.79%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Insmed, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.46

Surprise

-19.82%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

PTC Therapeutics, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.34

Actual

$0.61

Surprise

+75.59%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Bio-Techne Corp.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Bio-Techne Corp. reported EPS of $0.46, beating estimates by 3.95%, and revenue of $321.19M, 0.07% above expectations.

How did the market react to Bio-Techne Corp.'s Q2 2026 earnings?

The stock price moved up 0.11%, changed from $72.15 before the earnings release to $72.23 the day after.

When is Bio-Techne Corp. expected to report next?

The next earning report is scheduled for Nov 03, 2026.

What are the forecasts for Bio-Techne Corp.'s next earnings report?

Based on -- analysts, Bio-Techne Corp. is expected to report EPS of $0.45 and revenue of $297.20M for Q1 2027.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.